The FDA Offers First-Ever Guidelines For Psychedelic Trials & Studies

||, |

Lots of debate has surrounded the idea of psychedelics and their “legal” place in society. Over the past few years, we’ve seen more and more support for psychedelics, particularly psilocybin, in places like Oregon and Colorado. Colorado has now begun to shape the framework for psychedelics to be used in therapy.

This past weekend marked another monumental step in the right direction as the U.S Food and Drug Administration (FDA) published its first draft of guidance measures outlining recommendations to the pharmaceutical industry for designing clinical trials on psychedelic drugs.

According to the FDA:

“There has been a growing interest in the therapeutic potential of psychedelic drugs in recent years. They are being evaluated for use in potential treatment of conditions such as depression, PTSD, substance abuse disorders, and other conditions.”

These are just the very early steps of a very complex and delicate process but encouraging nonetheless. Many have believed for a long time that psychedelics contain valuable medicinal and therapeutic properties and it finally seems as though the world is catching on.